20 Juni 2012

Cannabis Catch-All?

Researchers in the U.K. are looking to breed marijuana to make medicines for metabolic disorders, epilepsy, and other diseases

GW Pharmaceuticals—the United Kingdom’s only legal cannabis production facility—imarijuana.jpgs already developing Sativex, a drug consisting of two principal cannabinoids (THC and CBD). Sativex is currently in Phase III trials for treating muscle spasticity in multiple sclerosis patients. But GW’s researchers are also studying how marijuana derivatives could be used to treat a much wider range of diseases, including metabolic disorders, epilepsy, ulcerative colitis, psychosis, brain injury, and cancer pain.

“As rigorous modern research with cannabinoids comes to fruition, a new era of treatment options may have arrived,” David Potter, director of Botanical Research and Cultivation at GW Pharmaceuticals who wrote about the company’s efforts this month in The Biologist, said in a press release.

…Full Text: http://the-scientist.com/2012/06/20/cannabis-catch-all/

Tags: THC, THCV, alternative medicines, non-traditional treatments

Source: The Scientist, 2012-06-20.

Supplier

Share on Twitter+1Share on FacebookShare on XingShare on LinkedInShare via email